证券代码：002742 证券简称：*ST三圣 公告编号：2025-69号 重庆三圣实业股份有限公司 关于重整计划资本公积转增股本事项实施的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、重庆市第五中级人民法院（以下简称"重庆五中院"或"法院"）于 2025 年 11 月 21 日裁定批准《重庆三圣实业股份有限公司重整计划》（以下简 称《重整计划》）。根据《重整计划》，重庆三圣实业股份有限公司（以下简 称"公司"或"三圣股份"）现有总股本 432,000,000 股，《重整计划》以三圣 股份 432,000,000 股流通股为基数，按每 10 股转增约 5.8356953935 股的比例实 施资本公积转增股本，共计转增 252,102,041 股（最终转增的准确股票数量以中 国证券登记结算有限责任公司深圳分公司实际登记确认的数量为准）。在转增 完成后，三圣股份的总股本增至 684,102,041 股。前述 252,102,041 股转增股票 不向原股东分配，其中 160,000,000 股用于引入重整投资人，92,102,041 股用于 清 ...

西南证券股份有限公司 关于 重庆三圣实业股份有限公司 调整资本公积转增股本 除权参考价格计算公式的专项意见 二〇二五年十二月 1 深圳证券交易所： 2024 年 12 月 18 日，重庆三圣实业股份有限公司（以下简称"三圣股份"、 "公司"、"上市公司"）与河北冀衡集团有限公司（以下简称"冀衡集团"）、深 圳市高新投集团有限公司（以下简称"高新投"）、重庆镭登恩私募证券投资基金 管理有限公司（以下简称"镭登恩私募"）签署了重整投资协议。2024 年 12 月 23 日，三圣股份与冀衡集团、高新投、镭登恩私募签署了重整投资协议的补充 协议。 2025 年 8 月 8 日，重庆市第五中级人民法院（以下简称"法院"）受理债 权人对公司的重整申请，并指定北京市金杜（深圳）律师事务所以及信永中和会 计师事务所（特殊普通合伙）重庆分所担任公司管理人（以下简称"管理人"）。 2025 年 11 月 14 日，三圣股份出资人组会议表决通过了《重庆三圣实业股 份有限公司重整计划（草案）之出资人权益调整方案》。2025 年 11 月 17 日，三 圣股份第二次债权人会议表决通过了《重庆三圣实业股份有限公司重整计划（草 案）》。2 ...

证券代码：002742 证券简称：*ST三圣 公告编号：2025-67号 重庆三圣实业股份有限公司 关于重整计划资本公积转增股本除权事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、公司重整情况概述 2025 年 8 月 8 日，重庆三圣实业股份有限公司（以下简称"公司"或"三 圣股份"）收到重庆市第五中级人民法院（以下简称"重庆五中院"或"法 院"）送达的（2025）渝 05 破申 224 号《民事裁定书》，重庆五中院裁定受理 公司的重整申请。同日，公司收到重庆五中院送达的（2025）渝 05 破 297 号 《决定书》，重庆五中院指定北京市金杜（深圳）律师事务所和信永中和会计 师事务所（特殊普通合伙）重庆分所担任公司管理人。具体内容详见公司于 2025 年 8 月 8 日在指定信息披露媒体披露的《关于法院裁定受理公司重整并指 定管理人暨公司股票交易将被叠加实施退市风险警示的公告》（公告编号： 2025-45 号）。 2025 年 10 月 30 日，公司披露了《重庆三圣实业股份有限公司重整计划 （草案）》（以下简称《重整计划草案》）、《重庆三 ...

证券代码：002742 证券简称：*ST三圣 公告编号：2025-68号 重庆三圣实业股份有限公司 关于公司股价向下除权的风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 重庆市第五中级人民法院（以下简称"重庆五中院"或"法院"）于 2025 年 11 月 21 日裁定批准《重庆三圣实业股份有限公司重整计划》（以下简称 《重整计划》），重庆三圣实业股份有限公司（以下简称"公司"或"三圣股 份"）进入重整计划执行阶段。根据《重整计划》，结合公司初步测算情况， 预计《重整计划》实施后公司股价存在向下除权调整的风险，具体情况以公司 后续公告为准。敬请广大投资者理性投资，注意投资风险。 一、公司股价存在向下除权调整的风险 根据《重整计划》，三圣股份现有总股本 432,000,000 股，以 432,000,000 股流通股为基数，按每 10 股转增约 5.8356953935 股的比例实施资本公积转增 股本，共计转增 252,102,041 股（最终转增的准确股票数量以中国证券登记结算 有限责任公司深圳分公司实际登记确认的数量为准）。在转增完成 ...

证券代码：002742 证券简称：*ST 三圣 公告编号：2025-66 号 重庆三圣实业股份有限公司 关于控股股东所持公司部分股份 将被二次司法拍卖的提示性公告 2、鉴于本次股东部分股份被司法拍卖事项尚处于公示阶段，根据相关规定 法院有权在拍卖开始前、拍卖过程中，中止拍卖或撤回拍卖，后续可能涉及竞 拍、缴款、股权变更过户等环节，拍卖结果存在不确定性。 一、控股股东股份被拍卖的基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次司法处置标的为公司控股股东潘先文先生持有的公司 280 万股股份， 占公司总股本的 0.6481%。本次司法拍卖事项不会导致公司控制权发生变更，不 会对公司的正常生产经营产生重大影响。 重庆三圣实业股份有限公司（以下简称"公司"）控股股东潘先文先生所持 280 万股公司股份于 2025 年 11 月 25 日 10 时起至 2025 年 11 月 26 日 10 时止在 淘宝网司法拍卖平台上进行第一次拍卖，显示结果为流拍，具体内容详见公司分 别于 2025 年 10 月 25 日、2025 年 11 月 27 ...

证券代码：002742 证券简称：三圣股份 公告编号：2025-65 号 重庆三圣实业股份有限公司 关于控股股东所持公司股份被司法拍卖流拍的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆三圣实业股份有限公司（以下简称"公司"）于 2025 年 10 月 25 日在巨 潮资讯网上披露了《关于控股股东所持公司股份将被司法拍卖的提示性公告》（公 告编号：2025-56），公司控股股东潘先文先生持有的公司 280 万股股份于 2025 年 11 月 25 日 10 时起至 2025 年 11 月 26 日 10 时止在淘宝网司法拍卖平台上（网 址：https://sf.taobao.com/）进行司法拍卖。根据淘宝网司法拍卖平台显示的 拍卖结果，本次拍卖流拍，具体情况如下： 重庆三圣实业股份有限公司董事会 1、本次控股股东所持有公司的股份司法拍卖流拍事项不会对公司的生产经 营产生重大影响。 2、公司将持续关注重庆市北碚区人民法院对上述公司股份后续处理的进展 情况，并按照相关规定及时履行信息披露义务。公司所有信息均以在指定媒体刊 登的信息为准。敬请广大投资者 ...

Core Points - Chongqing Sansheng Industrial Co., Ltd. has received a total of RMB 254,200,000.00 from all restructuring investors as of November 24, 2025 [1][2] - The restructuring investment agreements were signed with Hebei Jiheng Group Co., Ltd. and its designated financial investors, which include Shenzhen High-tech Investment Group Co., Ltd. and Chongqing Leiden Investment Fund Management Co., Ltd. [1] - The total restructuring investment amount was required to be paid within 30 days after the court's approval of the restructuring plan [1] Restructuring Investment Agreement - The restructuring investment agreements were signed on December 18 and December 23, 2024, with a total investment amount of RMB 254,200,000.00 [1] - The agreements stipulate that all restructuring investors must pay the total investment amount within the specified timeframe [1] Payment Status - As of November 24, 2025, the management account has received the full amount of the restructuring investment from all investors [2]

Group 1: Financial Products and Investment Performance - The issue of inflated returns on bank wealth management products has gained significant attention, with many investors reporting discrepancies between advertised and actual returns [1] - Industry experts call for standardized performance displays and emphasize the need for investors to develop a more professional and rational understanding of performance benchmarks [1] - Liang Hong, a prominent private equity manager, publicly apologized for underperforming against major indices, attributing the decline to three main factors: heavy investments in innovative drugs, hardware companies, and stablecoin stocks [1][2] Group 2: Robotics and Electric Vehicles - The Ministry of Industry and Information Technology announced the establishment of a standardization committee for humanoid robots, with representatives from several listed companies included [2] - According to TrendForce, global sales of new energy vehicles reached 5.39 million units in Q3 2025, marking a 31% year-on-year increase, with battery electric vehicles (BEVs) growing by 48% [2] Group 3: Corporate Developments and Investments - Tuozhu denied reports of Tencent's investment in its latest funding round, stating that no current financing is taking place [3] - Jiangxi Changyun announced plans to publicly transfer land use rights and assets for 7.787 million yuan [5] - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund focused on the intelligent industry [6] - Jusaylong intends to increase its subsidiary's capital by 170 million yuan through a debt-to-equity swap [7] - ST Sansheng received 254 million yuan from restructuring investors [8] - Lege Co., Ltd. plans to repurchase shares worth 40 to 80 million yuan [9] - Petty Co., Ltd. announced a share buyback plan of 50 to 70 million yuan [11] Group 4: Market Performance - The market showed a rebound with all major indices closing in the green, driven by strong performances in the aerospace, military, and AI application sectors [15] - The total trading volume in the Shanghai and Shenzhen markets was 1.73 trillion yuan, reflecting a decrease from the previous trading day [15]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Points - *ST San Sheng has received a total of RMB 254,200,000.00 from all restructuring investors as of November 24, 2025, marking the completion of all restructuring investment payments [1] Financial Summary - The total amount received from restructuring investors is RMB 254.2 million [1] - All restructuring investors have fully paid their respective investment amounts [1]